| # | Title | Journal | Year | Citations |
|---|
| 1 | Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial | Lancet Oncology, The | 2016 | 594 |
| 2 | p53-deficient mice are extremely susceptible to radiation-induced tumorigenesis | Nature Genetics | 1994 | 347 |
| 3 | Disulfiram modulated ROS–MAPK and NFκB pathways and targeted breast cancer cells with cancer stem cell-like properties | British Journal of Cancer | 2011 | 326 |
| 4 | Distinct genetic loci control development of benign and malignant skin tumours in mice | Nature Genetics | 1995 | 120 |
| 5 | Bevacizumab is equally effective and no more toxic in elderly patients with advanced colorectal cancer: a subgroup analysis from the AGITG MAX trial: an international randomised controlled trial of Capecitabine, Bevacizumab and Mitomycin C | Annals of Oncology | 2012 | 111 |
| 6 | A phase I and pharmacokinetic study of the combination of capecitabine and docetaxel in patients with advanced solid tumours | British Journal of Cancer | 2000 | 110 |
| 7 | Mechanistic and Predictive Profiling of 5-Fluorouracil Resistance in Human Cancer Cells | Cancer Research | 2004 | 102 |
| 8 | Neoadjuvant Therapy in Early Breast Cancer: Treatment Considerations and Common Debates in Practice | Clinical Oncology | 2017 | 85 |
| 9 | Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient data | Gynecologic Oncology | 2019 | 74 |
| 10 | Does body mass index affect progression-free or overall survival in patients with ovarian cancer? Results from SCOTROC I trial | Annals of Oncology | 2008 | 69 |
| 11 | Transgenic mice and squamous multistage skin carcinogenesis | Cancer and Metastasis Reviews | 1995 | 46 |
| 12 | Mechanisms of acquired chemoresistance to 5-fluorouracil and tomudex: thymidylate synthase dependent and independent networks | Cancer Chemotherapy and Pharmacology | 2007 | 39 |
| 13 | Assessing the impact of COVID-19 on liver cancer management (CERO-19) | JHEP Reports | 2021 | 36 |
| 14 | A phase II trial of bryostatin-1 administered by weekly 24-hour infusion in recurrent epithelial ovarian carcinoma | British Journal of Cancer | 2003 | 35 |
| 15 | The effect of different etiologies of hepatic impairment on the pharmacokinetics of gefitinib | Cancer Chemotherapy and Pharmacology | 2011 | 28 |
| 16 | CX-072 (pacmilimab), a Probody®PD-L1 inhibitor, in advanced or recurrent solid tumors (PROCLAIM-CX-072): an open-label dose-finding and first-in-human study | | 2021 | 26 |
| 17 | Chromosomal and genetic alterations of 7,12- Dimethylbenz[a]anthracene–induced melanoma from TP-ras transgenic mice | | 1997 | 25 |
| 18 | Comprehensive Characterization of the Vascular Effects of Cisplatin-Based Chemotherapy in Patients With Testicular Cancer | JACC: CardioOncology | 2020 | 20 |
| 19 | Trastuzumab-induced Radiation Recall Dermatitis — First Reported Case | Clinical Oncology | 2009 | 18 |
| 20 | Pancreatic cancer genomics: where can the science take us? | Clinical Genetics | 2015 | 13 |
| 21 | Lenvatinib therapy for the treatment of patients with advanced renal cell carcinoma | Future Oncology | 2016 | 13 |
| 22 | Trifluridine/Tipiracil in Metastatic Colorectal Cancer: A UK Multicenter Real-world Analysis on Efficacy, Safety, Predictive and Prognostic Factors | Clinical Colorectal Cancer | 2021 | 10 |
| 23 | Large cell neuroendocrine lung carcinoma: consensus statement from The British Thoracic Oncology Group and the Association of Pulmonary Pathologists | British Journal of Cancer | 2021 | 10 |
| 24 | Allele-specific loss or imbalance of chromosomes 9, 15, and 16 in B-cell tumors from interspecific F1 hybrid mice carrying e?-c-myc or N-myc transgenes | International Journal of Cancer | 2000 | 8 |
| 25 | Case report: immune-mediated cerebellar ataxia secondary to anti-PD-L1 treatment for lung cancer | International Journal of Neuroscience | 2019 | 6 |
| 26 | Incidence and impact of abnormal liver function in patients receiving adjuvant chemotherapy for early breast cancer. | | 2009 | 6 |
| 27 | Neoadjuvant chemotherapy and trastuzumab versus neoadjuvant chemotherapy followed by post-operative trastuzumab for patients with HER2-positive breast cancer | Oncotarget | 2016 | 5 |
| 28 | Three cases of thyroid cancer following the diagnosis of testicular cancer: treatment-related complication or genetics? | Scottish Medical Journal | 2016 | 3 |
| 29 | Multigenic Control of Skin Tumour Development in Mice | Novartis Foundation Symposium | 1996 | 3 |
| 30 | A phase 1b/2, open-label, dose-escalation, and dose-confirmation study of eribulin mesilate in combination with capecitabine | British Journal of Cancer | 2019 | 2 |
| 31 | The association between deprivation and the incidence and survival of patients with hepatocellular carcinoma in the West of Scotland | Expert Review of Gastroenterology and Hepatology | 2021 | 2 |
| 32 | How to integrate biologicals in the continuum of care | European Journal of Cancer | 2009 | 0 |
| 33 | Gut microbial short chain fatty acids are associated with pathological complete response (pCR) after neoadjuvant chemotherapy for breast cancer | European Journal of Cancer | 2020 | 0 |
| 34 | Health-Related Quality of Life Outcomes With Two Different Starting Doses of Lenvatinib in Combination With Everolimus for Previously Treated Renal Cell Carcinoma | Oncologist | 2023 | 0 |
